- Home
- ACXP vs CERO Comparison
ACXP vs CERO Comparison
Compare ACXP & CERO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ACXP
- CERO
- Stock Information
- Founded
- ACXP 2017
- CERO 2017
- Country
- ACXP United States
- CERO United States
- Employees
- ACXP 4
- CERO N/A
- Industry
- ACXP Biotechnology: Pharmaceutical Preparations
- CERO
- Sector
- ACXP Health Care
- CERO
- Exchange
- ACXP Nasdaq
- CERO Nasdaq
- Market Cap
- ACXP 6.8M
- CERO 5.6M
- IPO Year
- ACXP 2021
- CERO N/A
- Fundamental
- Price
- ACXP $4.29
- CERO $5.40
- Analyst Decision
- ACXP Strong Buy
- CERO Strong Buy
- Analyst Count
- ACXP 3
- CERO 2
- Target Price
- ACXP $143.67
- CERO $45.00
- AVG Volume (30 Days)
- ACXP 73.5K
- CERO 306.1K
- Earning Date
- ACXP 11-12-2025
- CERO 08-22-2025
- Dividend Yield
- ACXP N/A
- CERO N/A
- EPS Growth
- ACXP N/A
- CERO N/A
- EPS
- ACXP N/A
- CERO N/A
- Revenue
- ACXP N/A
- CERO N/A
- Revenue This Year
- ACXP N/A
- CERO N/A
- Revenue Next Year
- ACXP N/A
- CERO N/A
- P/E Ratio
- ACXP N/A
- CERO N/A
- Revenue Growth
- ACXP N/A
- CERO N/A
- 52 Week Low
- ACXP $3.80
- CERO $4.27
- 52 Week High
- ACXP $44.00
- CERO $895.40
- Technical
- Relative Strength Index (RSI)
- ACXP 38.73
- CERO 32.06
- Support Level
- ACXP $4.02
- CERO $4.27
- Resistance Level
- ACXP $4.27
- CERO $7.60
- Average True Range (ATR)
- ACXP 0.53
- CERO 0.55
- MACD
- ACXP 0.10
- CERO -0.22
- Stochastic Oscillator
- ACXP 13.86
- CERO 28.36
About ACXP Acurx Pharmaceuticals Inc.
Acurx Pharmaceuticals Inc is a clinical stage biopharmaceutical company developing a new class of antibiotics for infections caused by bacteria listed as priority pathogens by the World Health Organization, Centers for Disease Control and Prevention and Food and Drug Administration. The company's approach is to develop antibiotic candidates with a Gram-positive selective spectrum. The Company's segment consists of the development of clinical and preclinical product candidates for the development of the Company's proprietary new therapies.
About CERO CERo Therapeutics Holdings Inc. Common Stock
CERo Therapeutics Holdings Inc is an innovative immunotherapy company advancing the development of next-generation engineered T cell therapeutics for the treatment of cancer. Its proprietary approach to T cell engineering, which enables it to integrate certain desirable characteristics of both innate and adaptive immunity into a single therapeutic construct, is designed to engage the body's full immune repertoire to achieve optimized cancer therapy. Its lead molecule is CER-1236, an autologous T-cell product that targets a novel tumor antigen, TIM-4 ligand.